Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Director Purchases 10,000 Shares

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Director Bernhardt G. Zeiher bought 10,000 shares of Amylyx Pharmaceuticals stock in a transaction dated Thursday, March 20th. The shares were bought at an average cost of $3.70 per share, with a total value of $37,000.00. Following the completion of the acquisition, the director now owns 10,000 shares of the company’s stock, valued at $37,000. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Amylyx Pharmaceuticals Stock Up 3.6 %

AMLX stock traded up $0.13 during trading hours on Monday, hitting $3.78. The company’s stock had a trading volume of 400,828 shares, compared to its average volume of 1,387,702. The stock has a 50 day moving average price of $3.51 and a two-hundred day moving average price of $4.00. Amylyx Pharmaceuticals, Inc. has a 12 month low of $1.58 and a 12 month high of $7.27. The company has a market capitalization of $334.92 million, a PE ratio of -0.99 and a beta of -0.51.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last posted its earnings results on Tuesday, March 4th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.06). The business had revenue of ($0.67) million for the quarter. Sell-side analysts expect that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current year.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the business. Boxer Capital Management LLC bought a new stake in Amylyx Pharmaceuticals during the 4th quarter valued at approximately $6,615,000. Bank of America Corp DE boosted its position in shares of Amylyx Pharmaceuticals by 165.9% in the fourth quarter. Bank of America Corp DE now owns 2,426,263 shares of the company’s stock valued at $9,171,000 after acquiring an additional 1,513,748 shares during the period. Alpha Wave Global LP acquired a new stake in shares of Amylyx Pharmaceuticals in the third quarter worth $2,169,000. Walleye Capital LLC increased its position in Amylyx Pharmaceuticals by 986.5% during the third quarter. Walleye Capital LLC now owns 670,594 shares of the company’s stock worth $2,173,000 after acquiring an additional 608,874 shares during the period. Finally, Cubist Systematic Strategies LLC increased its position in Amylyx Pharmaceuticals by 862.5% during the fourth quarter. Cubist Systematic Strategies LLC now owns 472,397 shares of the company’s stock worth $1,786,000 after acquiring an additional 423,316 shares during the period. 95.84% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of Amylyx Pharmaceuticals in a report on Wednesday, March 5th. Three equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.33.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.